Evidence map›Paper›PMID 32097458›Full record

ArticleBlood advances2020

Stem cell donors should be screened for CHIP.

Amy E DeZern, Lukasz P Gondek

Abstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Allogeneic Transplantation for Older Adults.Advances in experimental medicine and biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  15. Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.Mediterranean journal of hematology and infectious diseases · 2022
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amy E DeZernThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Lukasz P GondekThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Hedgehog Signaling in the Progression of Myelodysplastic SyndromesK08HL136894 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GONDEK, LUKASZ PAWEL · 2017 to 2021
$859k
Personalized molecular approaches to disease monitoring and maintenance therapies for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) patients undergoing allogeneic bone marrow transpR21HL143096 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GONDEK, LUKASZ PAWEL · 2018 to 2019
$246k
Advancing Diagnostics and Therapeutics in Bone Marrow FailureR03HL136797 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DEZERN, AMY E · 2017 to 2018
$164k
NCI NIH HHS P30 CA006973NHLBI NIH HHS K08 HL136894NHLBI NIH HHS R03 HL136797NHLBI NIH HHS R21 HL143096
6 · The paper itself

Abstract

This article has a companion Counterpoint by Gibson and Lindsley.

Indexed as

Stem Cells

Identifiers

PMID32097458
PMCPMC7042978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.